Pharming announces that its Chief Executive Officer, Sijmen de Vries, will present at the Jefferies Healthcare Conference 2022, a hybrid meeting based in New York, at 22:00-22:30 CET/16:00-16:30 EDT on 9 June 2022.

Pharming Group N.V. announces that at its Annual General Meeting of shareholders (AGM), held today, all proposals were approved.  

Pharming Group N.V. presents its (unaudited) financial report for the first quarter of the year ended 31 March 2022.

Pharming confirms it will announce financial results for the first quarter of the year ended 31 March 2022 on Thursday, 12 May 2022.

An agreed Paediatric Investigation Plan (PIP) is the regulatory pathway to market authorization for leniolisib as a treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) in children. A Promising Innovative Medicine (PIM) designation is an early indication that leniolisib is a candidate for the MHRA’s Early Access to Medicines Scheme

Following an agreed investment by European investment company Gimv, Pharming’s minority stake of 43.85% in BioConnection will reduce to 22.98%. As a result of this transaction, Pharming will receive one-off US$ 7.5 million (EUR 6.9 million) net cash proceeds.

Pharming announces the filing of its Annual Report for the year ended 31 December 2021. The Company has also filed its Form 20-F with the U.S. Securities and Exchange Commission (SEC) for the same period. In addition, the company convenes its 2022 AGM.

Pharming Group announces new data from the pivotal Phase II/III trial of leniolisib for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a primary immunodeficiency.

Pharming announces that Principal Investigator V. Koneti Rao, MD, FRCPA, a staff physician in the Primary Immune Deficiency Clinic at the National Institutes of Health in Bethesda, Maryland, will present positive findings from the Phase III pivotal clinical trial of leniolisib for patients with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) at the Clinical Immunology Society (CIS) 2022 Annual Meeting in Charlotte, North Carolina.

Pharming Group presents its preliminary financial report for the full year ended December 31, 2021.